> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period Determined for Veltassa
- URL: https://www.fdaweb.com/regulatory-review-period-determined-for-veltassa/
- Published: 2017-11-29T12:00:00.000Z
- Updated: 2026-09-14T23:04:00.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140224

*Federal Register* notice: FDA has determined that the regulatory review period for patent extension purposes for Relypsa’s Veltassa (patiromer sorbitex calcium), indicated for treating hyperkalemia, is 2,844 days. Of this, 2,478 days occurred during the testing phase and 366 days occurred during the approval phase. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-11-29/pdf/2017-25761.pdf?ref=fdaweb.com).